Sotrovimab administration in vaccinated and unvaccinated kidney transplant recipients with SARS-CoV-2 infection: Correspondence.

Dear Editor,

We would like to correspond on the publication “Comparative outcomes after early Sotrovimab administration in vaccinated and unvaccinated kidney transplant recipients with SARS‐CoV‐2 infection during the Delta and Omicron BA.1 surges.” Although 21.6% of KTRs advanced to severe COVID‐19 infection despite Sotrovimab treatment during Delta and BA.1 Omicron surges, treatment within 4 days of symptom onset reduced disease severity.1 More efficient vaccines and therapeutic options are required, as mentioned by Vathsala et al., for susceptible populations, particularly in light of the SARS‐CoV‐2 virus's tendency to adapt and evade both natural and vaccine‐induced immunity, as well as current immunological therapies.1

We all agree that sotrovimab administration should be beneficial. However, the association with vaccination history must be interpreted with caution. The current report is based on the history of immunization and assumes that the COVID‐19 vaccine has a protective effect. However, antecedent asymptomatic COVID‐19, which is fairly common, is another probable confounding factor. If the background immunological condition of the cases is thoroughly investigated, the effect of sotrovimab administration can be more strongly established.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

FUNDING INFORMATION

The authors received no funding for this work.